Tethis S.p.A Secures $15 Million in Funding to Revolutionize Liquid Biopsy Diagnostics

Tethis S.p.A. is thrilled to announce the closing of a substantial funding round, raising €15 million to further propel its innovative goals within the oncology diagnostics field. As a pioneering company in the realm of liquid biopsy, Tethis is dedicated to making this advanced diagnostic method standard and reproducible. Our proprietary slides enable immediate, fully automated, and gentle processing of blood samples—key factors that enhance standardization and preserve clinical informativity. With this recent funding, we aim to enhance our high throughput analytical protocols which facilitate the sensitive and specific testing required for blood-based cancer detection across various clinical settings. This investment will not only accelerate the development of our technology but also support our efforts to improve patient outcomes by offering clinicians a reliable and efficient tool for cancer diagnosis. With a mission to transform the landscape of oncology diagnostics, Tethis is set to make significant strides in standardizing liquid biopsies, ultimately providing patients with quicker access to critical information about their health. We are grateful for the support of our investors, who share our vision for a future where early and precise cancer detection is within reach for everyone.